Mantle cell lymphoma (MCL) is a well-defined lymphoid malignancy characterized by a
rapid clinical evolution and poor response to current therapeutic protocols. The genetic and …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-
Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to …

Background Fluorescence in situ hybridization has improved the detection of genomic
aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal …

We used gene expression profiling to establish a molecular diagnosis of mantle cell
lymphoma (MCL), to elucidate its pathogenesis, and to predict the length of survival of these …

Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-
Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of …

We analyzed lymphocyte morphology, histology, immunophenotype, immunoglobulin heavy
chain (IgV H) gene mutations, and clinical course in 80 unselected patients presenting with …

Mantle cell lymphoma (MCL) is a lymphoid neoplasm characterized by a monomorphic
proliferation of small-to medium-sized lymphoid cells with irregular nuclei of B cell …

Mantle cell lymphoma (MCL) is characterized by 11q13 chromosomal translocation and
CCND1 overexpression, but additional genomic changes are also important for …

Differential gene expression analysis, using high-density microarray chips, demonstrated
300–400 genes to be deregulated in mantle cell lymphomas (MCLs) compared with normal …